RIPK3 and B-cell chronic lymphocytic leukemia: Moreover, we proceeded to re-capitulate these in vitro cell line findings by pre-treating primary CLL cells with inhibitors of key components of the necroptotic pathway: the RIPK1 inhibitor necrostatin-1 (NEC-1) and the RIPK3 inhibitor GSK’872 [61–63] (Fig. 2A), prior to incubation with scaffolded SRF231.